456 related articles for article (PubMed ID: 17549380)
1. Anti-tumor effects of immunotherapeutic peptide on the treatment of hepatocellular carcinoma with HBc carrier.
Kong J; Diao Z; Deng X; Zhong H; Yao W; Hu X
Oncol Rep; 2007 Jul; 18(1):279-85. PubMed ID: 17549380
[TBL] [Abstract][Full Text] [Related]
2. Generation of chimeric HBc proteins with epitopes in E.coli: formation of virus-like particles and a potent inducer of antigen-specific cytotoxic immune response and anti-tumor effect in vivo.
Zhang Y; Song S; Liu C; Wang Y; Xian X; He Y; Wang J; Liu F; Sun S
Cell Immunol; 2007 May; 247(1):18-27. PubMed ID: 17707782
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma.
Mizukoshi E; Nakamoto Y; Marukawa Y; Arai K; Yamashita T; Tsuji H; Kuzushima K; Takiguchi M; Kaneko S
Hepatology; 2006 Jun; 43(6):1284-94. PubMed ID: 16729333
[TBL] [Abstract][Full Text] [Related]
4. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
Komori H; Nakatsura T; Senju S; Yoshitake Y; Motomura Y; Ikuta Y; Fukuma D; Yokomine K; Harao M; Beppu T; Matsui M; Torigoe T; Sato N; Baba H; Nishimura Y
Clin Cancer Res; 2006 May; 12(9):2689-97. PubMed ID: 16675560
[TBL] [Abstract][Full Text] [Related]
5. Inducing oral immune regulation of hepatitis B virus envelope proteins suppresses the growth of hepatocellular carcinoma in mice.
Gotsman I; Alper R; Klein A; Rabbani E; Engelhardt D; Ilan Y
Cancer; 2002 Jan; 94(2):406-14. PubMed ID: 11900226
[TBL] [Abstract][Full Text] [Related]
6. Improvement of dendritic-based vaccine efficacy against hepatitis B virus-related hepatocellular carcinoma by two tumor-associated antigen gene-infected dendritic cells.
Yang JY; Cao DY; Xue Y; Yu ZC; Liu WC
Hum Immunol; 2010 Mar; 71(3):255-62. PubMed ID: 20036295
[TBL] [Abstract][Full Text] [Related]
7. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.
Shang XY; Chen HS; Zhang HG; Pang XW; Qiao H; Peng JR; Qin LL; Fei R; Mei MH; Leng XS; Gnjatic S; Ritter G; Simpson AJ; Old LJ; Chen WF
Clin Cancer Res; 2004 Oct; 10(20):6946-55. PubMed ID: 15501973
[TBL] [Abstract][Full Text] [Related]
8. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
[TBL] [Abstract][Full Text] [Related]
9. Induction of cytotoxic T lymphocytes from the peripheral blood of a hepatocellular carcinoma patient using melanoma antigen-1 (MAGE-1) peptide.
Lu J; Leng X; Peng J; Mou D; Pang X; Shang X; Chen W
Chin Med J (Engl); 2002 Jul; 115(7):1002-5. PubMed ID: 12150730
[TBL] [Abstract][Full Text] [Related]
10. Augmented induction of CD8+ cytotoxic T-cell response and antitumor effect by DCs pulsed with virus-like particles packaging with CpG.
Song S; Wang Y; Zhang Y; Wang F; He Y; Ren D; Guo Y; Sun S
Cancer Lett; 2007 Oct; 256(1):90-100. PubMed ID: 17656012
[TBL] [Abstract][Full Text] [Related]
11. Patient-derived dendritic cells transduced with an a-fetoprotein-encoding adenovirus and co-cultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against hepatocellular carcinoma cells.
González-Carmona MA; Märten A; Hoffmann P; Schneider C; Sievers E; Schmidt-Wolf IG; Sauerbruch T; Caselmann WH
Liver Int; 2006 Apr; 26(3):369-79. PubMed ID: 16584401
[TBL] [Abstract][Full Text] [Related]
12. Impact of occult hepatitis B virus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus.
Adachi S; Shibuya A; Miura Y; Takeuchi A; Nakazawa T; Saigenji K
Scand J Gastroenterol; 2008; 43(7):849-56. PubMed ID: 18584524
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy with CX3CL1/Fractalkine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma.
Tang L; Hu HD; Hu P; Lan YH; Peng ML; Chen M; Ren H
Gene Ther; 2007 Aug; 14(16):1226-34. PubMed ID: 17597794
[TBL] [Abstract][Full Text] [Related]
14. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma.
Korangy F; Ormandy LA; Bleck JS; Klempnauer J; Wilkens L; Manns MP; Greten TF
Clin Cancer Res; 2004 Jul; 10(13):4332-41. PubMed ID: 15240519
[TBL] [Abstract][Full Text] [Related]
15. [Immunogenicity of new DNA vaccine encoding for hepatitis B virus core antigen].
Xing YP; Huang ZH; Wang SX; Cai J; Li J; Lu S
Zhonghua Gan Zang Bing Za Zhi; 2004 Jun; 12(6):338-40. PubMed ID: 15225426
[TBL] [Abstract][Full Text] [Related]
16. Hemagglutinating virus of Japan protein is efficient for induction of CD4+ T-cell response by a hepatitis B core particle-based HIV vaccine.
Takeda S; Shiosaki K; Kaneda Y; Nakasatomi T; Yoshizaki H; Someya K; Konno Y; Eda Y; Kino Y; Yamamoto N; Honda M
Clin Immunol; 2004 Jul; 112(1):92-105. PubMed ID: 15207786
[TBL] [Abstract][Full Text] [Related]
17. [The significance of anti-HBc and occult hepatitis B virus infection in the occurrence of hepatocellular carcinoma in patients with HBsAg and anti-HCV negative alcoholic cirrhosis].
Kim MJ; Kwon OS; Chung NS; Lee SY; Jung HS; Park DK; Ku YS; Kim YK; Kim YS; Kim JH
Korean J Hepatol; 2008 Mar; 14(1):67-76. PubMed ID: 18367859
[TBL] [Abstract][Full Text] [Related]
18. Induction of specific cytolytic T lymphocytes using fusions of hepatocellular carcinoma (HCC) patient-derived dendritic cells and allogeneic HCC cell line.
Yin XY; Wang L; Lu MD; Li BJ; Huang JF
Hepatogastroenterology; 2008; 55(81):155-9. PubMed ID: 18507097
[TBL] [Abstract][Full Text] [Related]
19. [CTLs induced by hTERT-related multiepitope peptide-sensitived mDCs specifically kill HLA-A24+ tumor cells].
Shen HP; Niu BL; DU HM; Zou LQ; Gong JP
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2011 Jun; 27(6):626-30. PubMed ID: 21651861
[TBL] [Abstract][Full Text] [Related]
20. Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis.
Stroffolini T; Almasio PL; Persico M; Bollani S; Benvegnù L; Di Costanzo G; Pastore G; Aghemo A; Stornaiuolo G; Mangia A; Andreone P; Stanzione M; Mazzella G; Saracco G; Del Poggio P; Bruno S;
Am J Gastroenterol; 2008 Aug; 103(8):1966-72. PubMed ID: 18637087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]